Company Overview and News

 
Shipping firms look to register abroad if govt scraps benefits

2018-07-11 livemint
Mumbai: Indian shipping firms are threatening to “flag out” and register in foreign territories if the government removes one of the last few protections that they still enjoy. Great Eastern Shipping and Shreyas Shipping —two of the largest private shipping lines in the country—are mulling the option of moving to more tax-friendly jurisdictions as the government gradually removes these benefits.
GESHIP 500620

 
Great Eastern board to consider raising up to Rs 1,000 cr via NCDs

2018-04-23 moneycontrol
Great Eastern Shipping Ltd today said its board will next month decide on raising up to Rs 1,000 crore through private placement of non-convertible debentures (NCDs).
GESHIP 500620

 
Company News: Great Eastern Shipping Company

2018-04-19 thehindubusinessline
Great Eastern Shipping Company has taken delivery of a second-hand very large gas carrier ‘Jag Viraat’ (2007 built) of about 81,617 cbm. The company had contracted to buy the vessel earlier this month. GE Shipping’s current fleet stands at 48 vessels, comprising 33 tankers (12 crude carriers, 17 product tankers, 4 LPG carriers) and 15 dry bulk carriers (1 capesize, 8 Kamsarmax, 6 Supramax) with an average age of 10.
GESHIP 500620

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

10h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

10h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

12h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...